Global Rheumatoid Arthritis Drugs/Therapeutics Market valued approximately USD 22.14 billion in 2018 is anticipated to grow with a healthy growth rate of more than 4.50% over the forecast period 2019-2026. The Rheumatoid Arthritis Drugs/Therapeutics Market is continuously growing in the global scenario at significant pace. Rheumatoid arthritis (RA) is the most common type of autoimmune chronic disease that causes joint pain, swelling and stiffness in joint and even loss of joint function. To overcome this diseases various medications are introduced such as disease-modifying anti-rheumatic drugs (DMARDs), biological response modifiers (a type of DMARD), glucocorticoids, analgesics (painkillers) and nonsteroidal anti-inflammatory medications (NSAIDs). DMARDs have significantly enhanced the quality of life for numerous people suffering from rheumatoid arthritis. Rising geriatric population worldwide, increasing prevalence of rheumatoid and structured reimbursement & regulatory framework are the substantial driving factors of the market during the forecast period. Additionally, increasing awareness regarding diseases remittances therapies and growing healthcare expenditure are another factor that impelling the demand of rheumatoid arthritis drugs across the globe. Moreover, rise in need of Rheumatoid Arthritis Drugs/Therapeutics due to increasing prevalence of disease is the factors that likely to create numerous opportunity in the near future. However, patient expiration of many leading drugs is one of the major factors that limiting the growth of the market during the forecast period.

The regional analysis of Global Rheumatoid Arthritis Drugs/Therapeutics Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share due to rising awareness associated with the disease, growing healthcare expenditure and high adoption of biopharmaceuticals for the treatment in the region. Europe is estimated to grow at stable growth rate in the global Rheumatoid Arthritis Drugs/Therapeutics market over the upcoming years. Further, Asia-Pacific is anticipated to exhibit higher growth rate / CAGR over the forecast period 2019-2026 due to increasing adoption of rheumatoid arthritis drugs in the region.

The major market player included in this report are:
Abb Vie
Amgen Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb
F. Hoffmann-La Roche AG
Johnson & Johnson
Novartis International AG
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
UCB S.A.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Molecule Type:

Biopharmaceuticals
Pharmaceuticals

By Sales Channel:

Prescription
Over the Counter (OTC)

By Regions:

Furthermore, years considered for the study are as follows:

Historical year - 2016, 2017
Base year - 2018
Forecast period - 2019 to 2026

Target Audience of the Global Rheumatoid Arthritis Drugs/Therapeutics Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors